Eliem Therapeutics EPS - Earnings per Share 2021-2024 | CLYM
Eliem Therapeutics eps - earnings per share from 2021 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Eliem Therapeutics Annual EPS |
| 2023 |
$-1.30 |
| 2022 |
$-1.72 |
| 2021 |
$-4.24 |
| 2020 |
$-10.49 |
| Eliem Therapeutics Quarterly EPS |
| 2024-06-30 |
$-1.81 |
| 2024-03-31 |
$-0.06 |
| 2023-12-31 |
$-0.12 |
| 2023-09-30 |
$-0.15 |
| 2023-06-30 |
$-0.19 |
| 2023-03-31 |
$-0.84 |
| 2022-12-31 |
$-0.29 |
| 2022-09-30 |
$-0.37 |
| 2022-06-30 |
$-0.56 |
| 2022-03-31 |
$-0.50 |
| 2021-12-31 |
$5.27 |
| 2021-09-30 |
$-0.70 |
| 2021-06-30 |
$-3.11 |
| 2021-03-31 |
$-5.70 |
| 2020-12-31 |
$0.00 |
| 2020-09-30 |
$-1.46 |
| 2020-06-30 |
$-1.12 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
